Toward a design of affordable, topical microbicides: Acylcarnitine analogues

Current Pharmaceutical Design

Volumn 11, Issue 29, 2005, Pages 3757-3767

  Gandour, Richard D ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Acylcarnitine; Antifungal; HIV; Microbicide; Sexually transmitted infection; Spermicide

Indexed keywords

ACYLCARNITINE; AMPHOPHILE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BENZALKONIUM CHLORIDE; BETAINE; C31G; CARBOXYMETHYLCELLULOSE; CARNITINE; DETERGENT; DIPALMITOYLPHOSPHATIDYLCHOLINE; DOCUSATE SODIUM; DRUG VEHICLE; GLYMINOX; HEMIPAMITOYLCARNITINIUM; NONOXINOL 9; PALMITOYLCARNITINE; SAVVY; SPERMICIDAL AGENT; SURFACTANT; UNCLASSIFIED DRUG; VAGIPREV; Z 14; Z 15;

CANDIDIASIS; CHLAMYDIASIS; CLINICAL TRIAL; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; FEMALE FERTILITY; GONORRHEA; HAEMOPHILUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; STRUCTURE ACTIVITY RELATION; VAGINA DISEASE;

ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; CARNITINE; CHEMISTRY, PHYSICAL; DRUG DESIGN; HUMANS; SPERMATOCIDAL AGENTS;

EID: 27744602414     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774580705     Document Type: Review

References (77)

1. Potts M. The urgent need for a vaginal microbicide in the prevention of HIV transmission. Am J Public Health 1994; 84: 890-1.
2. McCormack S, Hayes R, Lacey CJN, Johnson AM. Science, medicine, and the future: Microbicides in HIV prevention. BMJ 2001; 322: 410-413.
3. Elias C, Coggins C. Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: Where have we been? Where are we going? J Womens Health Gend Based Med 2001; 10: 163-73.
4. Mauck C, Doncel G. An Update on Vaginal Microbicides. Curr Infect Dis Rep 2001; 3: 561-568.
5. Turpin JA. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin Investig Drugs 2002; 11: 1077-97.
6. Stone A. Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat Rev Drug Discov 2002; 1: 977-85.
7. Keller MJ, Klotman ME, Herold BC. Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus. Am J Reprod Immunol 2003; 49: 279-84.
8. Garg S, Kandarapu R, Vermani K, Tambwekar KR, Garg A, Waller DP, et al. Development pharmaceutics of microbicide formulations. Part I: preformulation considerations and challenges. AIDS Patient Care STDS 2003; 17: 17-32.
9. Cohn SE, Clark RA. Sexually transmitted diseases, HIV, and AIDS in women. Med Clin North Am 2003; 87: 971-95.
10. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 2004; 10: 315-36.
11. Lambert PA. Membrane-active antimicrobial agents. Prog Med Chem 1978; 15: 87-124.
12. Watts DH, Rabe L, Krohn MA, Aura J, Hillier SL. The effects of three nonoxynol-9 preparations on vaginal flora and epithelium. J Infect Dis 1999; 180: 426-37.
13. Patton DL, Kidder GG, Sweeney YC, Rabe LK, Hillier SL. Effects of multiple applications of benzalkonium chloride and nonoxynol 9 on the vaginal epithelium in the pigtailed macaque (Macaca nemestrina). Am J Obstet Gynecol 1999; 180: 1080-7.
14. Fichorova RN, Tucker LD, Anderson DJ. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 184: 418-28.
15. Fichorova RN, Bajpai M, Chandra N, Hsiu JG, Spangler M, Ratnam V, et al. Interleukins (IL)-1, IL-6 and IL-8 Predict Mucosal Toxicity of Vaginal Microbicidal Contraceptives. Biol Reprod 2004.
16. Watanabe S, Regen SL. Quaternary Ammonium-Based Surfactants That Can Recognize Cholesterol-Rich Membranes and Proton-Ionizable Analogs That Cannot. J Am Chem Soc 1994; 116: 5762-5.
17. le Maire M, Champeil P, Moller JV. Interaction of membrane proteins and lipids with solubilizing detergents. Biochim Biophys Acta 2000; 1508: 86-111.
18. Sobel JD. Treatment of vaginal Candida infections. Expert Opin Pharmacother 2002; 3: 1059-65.
19. McGroarty JA, Soboh F, Bruce AW, Reid G. The spermicidal compound nonoxynol-9 increases adhesion of Candida species to human epithelial cells in vitro. Infect Immun 1990; 58: 2005-7.
20. Jonsson MK, Wahren B. Sexually transmitted herpes simplex viruses. Scand J Infect Dis 2004; 36: 93-101.
21. Nicander I, Rantanen I, Rozell BL, Soderling E, Ollmar S. The ability of betaine to reduce the irritating effects of detergents assessed visually, histologically and by bioengineering methods. Skin Res Technol 2003; 9: 50-58.
22. Thompson KA, Malamud D, Storey BT. Assessment of the antimicrobial agent C31G as a spermicide: comparison with nonoxynol-9. Contraception 1996; 53: 313-8.
23. Corner AM, Dolan MM, Yankell SL, Malamud D. C31G, a new agent for oral use with potent antimicrobial and antiadherence properties. Antimicrob Agents Chermother 1988; 32: 350-3.
24. Wyrick PB, Knight ST, Gerbig DG Jr, Raulston JE, Davis CH, Paul TR, et al. The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro. Antimicrob Agents Chemother 1997; 41: 1335-44.
25. Ballagh SA, Baker JM, Henry DM, Archer DF. Safety of single daily use for one week of C31G HEC gel in women. Contraception 2002; 66: 369-375.
26. Bax R, Douville K, McCormick D, Rosenberg M, Higgins J, Bowden M. Microbicides - evaluating multiple formulations of C31G. Contraception 2002; 66: 365-368.
27. Witherell GW. Glyminox (Biosyn). Curr Opin Investig Drugs 2004; 5: 222-31.
28. Ramsay RR, Gandour RD, van der Leij FR. Molecular enzymology of carnitine transfer and transport. Biochim Biophys Acta 2001; 1546: 21-43.
29. Eaton S. Control of mitochondrial beta-oxidation flux. Prog Lipid Res 2002; 41: 197-239.
30. Abe M, Yamazaki N, Suzuki Y, Kobayashi A, Ohta H. Effect of palmitoyl carnitine on Na+, K+-ATPase and adenylate, cyclase activity of canine myocardial sarcolemma. J Mol Cell Cardiol 1984; 16: 239-45.
31. Katoh N, Wrenn RW, Wise BC, Shoji M, Kuo JF. Substrate proteins for calmodulin-sensitive and phospholipid-sensitive Ca2+-dependent protein kinases in heart, and inhibition of their phosphorylation by palmitoylcarnitine. Proc Natl Acad Sci USA 1981; 78: 4813-7.
32. Wise BC, Kuo JF. Modes of inhibition by acylcarnitines, adriamycin and trifluoperazine of cardiac phospholipid-sensitive calcium-dependent protein kinase. Biochem Pharmacol 1983; 32: 1259-65.
33. Jeulin C, Lewin LM. Role of free L-carnitine and acetyl-L-carnitine in post-gonadal maturation of mammalian spermatozoa. Hum Reprod Update 1996; 2: 87-102.
34. Inaba K. Molecular architecture of the sperm flagella: molecules for motility and signaling. Zoolog Sci 2003; 20: 1043-56.
35. Ashizawa K, Kamiya T, Tamura I, Tsuzuki Y. Inhibition of flagellar motility of fowl spermatozoa by L-carnitine: its relationship with respiration and phosphorylation of axonemal proteins. Mol Reprod Dev 1994; 38: 318-25.
36. Brener E, Rubinstein S, Cohen G, Shternall K, Rivlin J, Breitbart H. Remodeling of the actin cytoskeleton during mammalian sperm capacitation and acrosome reaction. Biol Reprod 2003; 68: 837-45.
37. Cohen G, Rubinstein S, Gur Y, Breitbart H. Crosstalk between protein kinase A and C regulates phospholipase D and F-actin formation during sperm capacitation. Dev Biol 2004; 267: 230-41.
38. Sheridan R, Ratledge C. Changes in cell morphology and carnitine acetyltransferase activity in Candida albicans following growth on lipids and serum and after in vivo incubation in mice. Microbiology 1996; 142 (Pt 11): 3171-80.
39. Prakobphol A, Leffler H, Hoover CI, Fisher SJ. Palmitoyl carnitine, a lysophospholipase-transacylase inhibitor, prevents Candida adherence in vitro. FEMS Microbiol Lett 1997; 151: 89-94.
40. Chen SC, Wright LC, Golding JC, Sorrell TC. Purification and characterization of secretory phospholipase B, lysophospholipase and lysophospholipase/transacylase from a virulent strain of the pathogenic fungus Cryptococcus neoformans. Biochem J 2000; 347: 431-9.
41. Pagot Y, Belin JM. Involvement of carnitine acyltransferases in peroxisomal fatty acid metabolism by the yeast Pichia guillier-mondii. Appl Environ Microbiol 1996; 62: 3864-7.
42. Gandour RD, Colucci WJ, Stelly TC, Brady PS, Brady LJ. Activesite probes of carnitine acyltransferases. Inhibition of carnitine acetyltransferase by hemiacetylcarnitinium, a reaction intermediate analogue. Biochem Biophys Res Commun 1996; 138: 735-41.
43. Gandour RD, Colucci WJ, Stelly TC, Brady PS, Brady LJ, Hemipalmitoylcarnitinium, a strong competitive inhibitor of purified hepatic carnitine palmitoyltransferase. Arch Biochem Biophys 1988; 267: 515-20.
44. Gandour RD, Leung OT, Greway AT, Ramsay RR, Nic a'Bhaird N, Fronczek FR, et al. (+)-Hemipalmitoylcarnitinium strongly inhibits carnitine palmitoyltransferase-I in intact mitochondria. J Med Chem 1993; 36: 237-42.
45. Nic a'Bhaird N, Kumaravel G, Gandour RD, Krueger MJ, Ramsay RR. Comparison of the active sites of the purified carnitine acyltransferases from peroxisomes and mitochondria by using a reaction- intermediate analogue. Biochem J 1993; 294: 645-51.
46. Kumaravel G, Ashendel CL, Gandour RD. Hemicholinium and related lipids: inhibitors of protein kinase C. J Med Chem 1993; 36: 177-8.
47. Garcia-Huidobro T, Valenzuela E, Leisewitz AV, Valderrama J, Bronfman M. Anti-proliferative effect of two novel palmitoyl-carnitine analogs, selective inhibitors of protein kinase C conventional isoenzymes. Eur J Biochem 1999; 266: 855-864.
48. Savle PS, Doncel GF, Bryant SD, Hubieki MP, Robinette RG, Gandour RD. Acylcarnitine analogues as topical, microbicidal spermicides. Bioorg Med Chem Lett 1999; 9: 2545-8.
49. Sander FV, Cramer SD. A Practical Method of Testing the Spermicidal Action of Chemical Contraceptives. Hum Fertil 1941; 6: 134-137.
50. Doncel GF. In: Mauck CK, Cordero M, Gabelnick HL, Spieler JM, Rivera R (Eds), Barrier contraceptives: current status and future prosects. New York, Wiley-Liss 1994; 147.
51. Balgavy P, Devinsky F. Cut-off effects in biological activities of surfactants. Adv Colloid Interface Sci 1996; 66: 23-63.
52. Birnie CR, Malamud D, Schnaare RL. Antimicrobial Evaluation of N-Alkyl Betaines and N-Alkyl-N,N-Dimethylamine Oxides with Variations in Chain Length. Antimicrob Agents Chemother 2000; 44: 2514-2517.
53. Huibers PDT. Quantum-chemical calculations of the charge distribution in ionic surfactants. Langmuir 1999; 15: 7546-7550.
54. Resnick L, Busso ME, Duncan RC. In: Alexander NJ, Gabelnick HL, Spieler JM (Eds), Anti-HIV Screening Technology. Heterosexual Transmission of AIDS: Proceedings of the Second Contraceptive Research and Development (CONRAD) Program International Workshop, held in Norfolk, Virginia, February 1-3, 1989. New York, Wiley-Liss 1990; 311-325.
55. Warner KS, Li SK, He N, Suhonen TM, Chantasart D, Bolikal D, et al. Structure-activity relationship for chemical skin permeation enhancers: probing the chemical microenvironment of the site of action. J Pharm Sci 2003; 92: 1305-22.
56. Fassi A. Stable, non-hygroscopic salts of L(-)carnitine and alkanoyl L(-)carnitines, a process for their preparation and solid, orally administrable compositions containing such salts. U.S. patent 5, 952, 379, Sigma-Tau Industrie Farmaceutiche (September 14, 1999).
57. Doncel G, Savle P, Gandour R, Cooper M, Wood G, Bryant S. Acylcarnitine Analogues: New Vaginal Microbicides with Contraceptive and Low-Irritation Properties. Microbicides 2002. Antwerp, Belgium (2002) Abstract #A-238 http://www.itg.be/micro2002/downloads/abstracts.pdf
58. Gerbase AC, Rowley JT, Mertens TE. Global epidemiology of sexually transmitted diseases. Lancet 1998; 351 Suppl 3: 24.
59. Fraiz J, Jones RB. Chlamydial infections. Annu Rev Med 1988; 39: 357-70.
60. Farley TA, Cohen DA, Elkins W. Asymptomatic sexually transmitted diseases: the case for screening. Prev Med 2003; 36: 502-9.
61. Mardh PA. Tubal factor infertility, with special regard to chlamydial salpingitis. Curr Opin Infect Dis 2004; 17: 49-52.
62. Dan M. The use of fluoroquinolones in gonorrhoea: the increasing problem of resistance. Expert Opin Pharmacother 2004; 5: 829-54.
63. Tapsall J. Current concepts in the management of gonorrhoea. Expert Opin Pharmacother 2002; 3: 147-57.
64. Laga M, Manoka A, Kivuvu M, Malele B, Tuliza M, Nzila N, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993; 7: 95-102.
65. Bong CT, Bauer ME, Spinola SM. Haemophilus ducreyi: clinical features, epidemiology, and prospects for disease control. Microbes Infect 2002; 4: 1141-8.
66. Al-Tawfiq JA, Spinola SM. Haemophilus ducreyi: clinical disease and pathogenesis. Curr Opin Infect Dis 2002; 15: 43-7.
67. Lagergard T. Haemophilus ducreyi: pathogenesis and protective immunity. Trends Microbiol 1995; 3: 87-92.
68. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75: 3-17.
69. Lewis DA. Chancroid: clinical manifestations, diagnosis, and management. Sex Transm Infect 2003; 79: 68-71.
70. Cooper MD, Rapp J, Jeffery-Wiseman C, Barnes RC, Stephens DS. Chlamydia trachomatis infection of human fallopian tube organ cultures. J Gen Microbiol 1990; 136: 1109-15.
71. Anderson RA, Feathergill K, Diao X, Cooper M, Kirkpatrick R, Spear P, et al. Evaluation of poly(styrene-4-sulfonate) as a preventive agent for conception and sexually transmitted diseases. J Androl 2000; 21: 862-75.
72. Totten PA, Stamm WE. Clear broth and plate media for culture of Haemophilus ducreyi. J Clin Microbiol 1994; 32: 2019-23.
73. Eckstein P, Jackson MC, Millman N, Sobrero AJ. Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. J Reprod Fertil 1969; 20: 85-93.
74. Savle PS, Gandour RD, Doncel GF. Carnitine analogues as topical, microbicidal spermicides. U.S. Patent 6, 656, 936, Virginia Tech Intellectual Properties, Inc. (December 2, 2003).
75. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Design 2004: 10(3): 315-36.
76. Vierling P, Greiner J. Prodrugs of HIV protease inhibitors. Curr Pharm Design 2003; 9(22): 1755-70.
77. Wakabayashi H, Takase M, Tomita M. Lactoferricin derived from milk protein lactoferrin. Curr Pharm Design 2003; 9(16): 1277-87.